Amphastar Pharmaceuticals Inc vs iShares Gold Trust — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $868.62M), while iShares Gold Trust trades at $83. The key difference: iShares Gold Trust is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | IAU | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $30.81 | $101.57 |
52-Week Low | $16.87 | $62.49 |
Enterprise Value | $1.27B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
No Aura AI signal available yet.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →